Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Inclusion Criteria: * Male or female patients with cystic fibrosis confirmed by genetic testing and / or by sweat test * Colonization with P. aeruginosa confirmed in sputum in the past 12 months * Cohort 1: greater than or equal to 18 years of age. * Cohort 2: 6 - 12 years of age (inclusive) * Normal Body Mass Index: BMI between 14.5 and 30 kg/m2, but in no case lower than the 30th percentile for age. Because CF patients are typically smaller than non-CF-patients, the normal body mass index will be based on standard CF foundation normal values for weight and sex. * Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period. * Patients and legal representatives must have given their written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures Exclusion Criteria: * Patients with FEV1 \< 35% of predicted. FEV1 (forced expiratory volume) is a measure of lung function. This exclusion will prohibit enrollment of patients with severely impaired lung function. * Patients with Burkholderia cepacia colonization of their respiratory tract * Patients with acute bronchopulmonary aspergillosis (ABPA) * Patients on a lung transplant list * Patients with acute pulmonary exacerbations * Patients with severe liver cirrhosis * Massive hemoptysis in the preceding 4 weeks * A history of relevant diseases of vital organs, of the central nervous system, or other organs not related to the underlying disease * Patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies * Patients with hypersensitivity to the investigational drug or to other quinolones and/ or to inactive constituents * Patients with known intolerance to hypertonic saline or bronchodilators * Concomitant inhalation therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones * Women who are pregnant